![]() |
« Geospiza partners with Illumina | Main | FDA grants MediQuest's drug priority review »
Second in a series. I asked seven of the top biotech leaders in the city to name three colleagues who they thought were the most influential players in the industry here. This week, I'll showcase the names that came up most often among their responses.
Please e-mail me your own selections at joetartakoff@seattlepi.com. I'll showcase those on Friday.
At ZymoGenetics, CEO Bruce Carter is overseeing the launch of the company's first product, Recothrom, a synthetic protein designed to stop bleeding during surgery. It's too early to tell if the product is gaining much ground (some analysts say the launch is taking longer than expected) but Carter has promised that "We will be finished when we dominate this market."

Carter's accomplishments at ZymoGenetics are many. He led the negotiations that culminated in the spin off of ZymoGenetics from Novo Nordisk in 2000 and then oversaw the company's initial public offering two years later.
He has also negotiated partnerships with Merck Serono (jointly the two companies are developing Atacicept for the treatment of autoimmune, inflammatory diseases and cancer) and Bayer Schering (to commercialize Recothrom overseas and co-promote it in the United States). And despite recent layoffs, Carter still oversees a staff of 535 biotech employees that is second in number only to Amgen in the region.
Last month, Carter was tapped to lead the search for a new president of the Washington Biotechnology and Biomedical Association.
He is revered by his peers.
Says A. Bruce Montgomery, head of respiratory therapeutics at Gilead Sciences:
Influence requires outside the company action, respect, and likely internal success ... That said, I cast my three votes for Bruce Carter. He is in his own class. A former Olympian ... , scientist, business man, community man, and the guy you want to go have a drink with. His Churchill imitation is priceless. I sign my email to him as Bruce II, as I share a name with a giant, but clearly I am the lessor.
Adds Clay Siegall, CEO of Seattle Genetics:
He is the dean of all the corporate executives in town.
About that reference to the Olympics: Carter rowed with Great Britain's 8-man sweep boat in the 1968 Olympics in Mexico City.
! Login below to post a comment.
Unregistered users, sign up now
Or post anonymously (About this feature)

News tips or comments? E-mail me or call directly, 206-448-8293.
Most popular posts in July, by page views
1. Dendreon initiates new Provenge study
2. Allen Institute releases spinal cord map
3. Genentech, Roche – and Seattle Genetics
Excerpts from interviews
· Don Foster on Novo Nordisk
· Bruce Carter on ZymoGenetics
· Lee Huntsman on the Life Sciences Discovery Fund
· Clay Siegall on Seattle Genetics
· J. Michael French on MDRNA
· Jack Faris on the WBBA
A series on the blog taking stock of Seattle's biotech leaders
· Who are Seattle's most influential biotech leaders?
· The CEO: Bruce Carter
· The entrepreneur: Bruce Montgomery
· The investor: Alan Frazier
· Your choices
A series on the blog
· Seattle's contracting biotech job market
· Venture capital numbers here don't measure up
· A fall in the market value of local firms
Recent entries
· Stories to watch: ZGEN and SGEN
· Round-up: Dendreon, SonoSite
· Stories to watch: Provenge
· Stories to watch: Amgen's Elliott Bay plans
· Round-up: Cell Therapeutics, Amgen
RSS/Web feeds (help)




Blogs
· Pharmalot
· John Cook's Venture Blog
· blog.bioethics.net
· Eye on FDA
· In the Pipeline
· IN VIVO Blog
· The Biotech Weblog
· DrugWonks
· Biotech Blog
· BioHealth Investor
· Xconomy Seattle
· Andy's Take
Groups
· Washington Biotechnology and Biomedical Association
· Northwest Association for Biomedical Research
Rumors
· Biofind
Jobs
· WBBA Careers
· Medzilla
· BioJobBlog
Resources
· Clinicaltrials.gov

Reader Blog: Career Chic
Reader Blog: The Biz Bite
Reader Blog: In Good Company
Reader Blog: Start Her Up
more
more

101 Elliott Ave. W.
Seattle, WA 98119
(206) 448-8000
Home Delivery: (206) 464-2121 or (800) 542-0820
seattlepi.com serves about 1.7 million unique visitors
and 30 million page views each month.
Send comments to newmedia@seattlepi.com
Send investigative tips to iteam@seattlepi.com
©1996-2007 Seattle Post-Intelligencer
Terms of Use/Privacy Policy
